ADPT Adaptive Biotechnologies Corporation
Healthcare$14.08+0.00%OpenMarket Cap: $2.25B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
9.98
P/S
7.52
EV/EBITDA
-106.76
DCF Value
$-27.41
FCF Yield
-1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.3%
Operating Margin
-15.8%
Net Margin
-16.8%
ROE
-24.3%
ROA
-9.8%
ROIC
-10.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $70.9M | 73.6% | $-19.2M | $-20.0M | $— | — |
| Q4 null | $71.7M | 74.6% | $-12.8M | $-13.6M | $— | — |
| FY null | $277.0M | 74.2% | $-57.1M | $-59.5M | $— | — |
| Q3 null | $94.0M | 80.7% | $10.3M | $9.5M | $— | — |
| Q2 null | $58.9M | 69.4% | $-25.0M | $-25.6M | $— | — |
| Q1 null | $52.4M | 67.6% | $-29.6M | $-29.9M | $— | — |
| Q4 null | $47.5M | 62.0% | $-33.8M | $-33.7M | $— | — |
| FY null | $179.0M | 59.7% | $-162.5M | $-159.5M | $— | — |
| Q3 null | $46.4M | 64.1% | $-32.6M | $-32.1M | $— | — |
| Q2 null | $43.2M | 55.3% | $-47.3M | $-46.2M | $— | — |
| Q1 null | $41.9M | 56.9% | $-48.8M | $-47.5M | $— | — |
| Q4 2023 | $45.8M | 57.2% | $-71.1M | $-69.4M | $-0.48 | — |